STAT19m
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
What’s Happening With Amgen Stock?
As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...
STAT2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.
FierceBiotech2d
Hidden data on obesity prospect wipe $12B off Amgen market cap
The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 ...
MarketWatch2d
Amgen Says No Link Between MariTide, Bone Density Loss
Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after ...
Amgen issues statement regarding MariTide Phase 1 data
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...